Revance Therapeutics (RVNC) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Revance Therapeutics (NASDAQ: RVNC) in the last few weeks:

• 9/15/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/13/2024 – Revance Therapeutics had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $7.00 price target on the stock, down previously from $10.00.
• 9/7/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/30/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/22/2024 – Revance Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/13/2024 – Revance Therapeutics was downgraded by analysts at Needham & Company LLC from a “moderate buy” rating to a “hold” rating.
• 8/13/2024 – Revance Therapeutics was downgraded by analysts at HC Wainwright from a “strong-buy” rating to a “hold” rating.
• 8/12/2024 – Revance Therapeutics had its “neutral” rating reaffirmed by analysts at Guggenheim.
• 8/12/2024 – Revance Therapeutics had its “market perform” rating reaffirmed by analysts at William Blair.
• 8/12/2024 – Revance Therapeutics was downgraded by analysts at Piper Sandler from a “strong-buy” rating to a “hold” rating.
• 8/9/2024 – Revance Therapeutics had its price target lowered by analysts at Piper Sandler from $11.00 to $6.00. They now have an “overweight” rating on the stock.
• 8/9/2024 – Revance Therapeutics had its price target lowered by analysts at Stifel Nicolaus from $24.00 to $20.00. They now have a “buy” rating on the stock.
• 8/9/2024 – Revance Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.

Revance Therapeutics Stock Down 1.2 %

RVNC stock traded down $0.07 during mid-day trading on Friday, hitting $5.78. 898,417 shares of the company were exchanged, compared to its average volume of 2,854,970. The business has a fifty day simple moving average of $5.29 and a 200-day simple moving average of $4.30. The firm has a market capitalization of $605.86 million, a P/E ratio of -1.59 and a beta of 1.00. Revance Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $13.12.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The firm had revenue of $65.39 million during the quarter, compared to analysts’ expectations of $66.30 million. During the same period in the previous year, the firm earned ($0.80) EPS. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year.

Institutional Trading of Revance Therapeutics

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC acquired a new stake in Revance Therapeutics during the 4th quarter worth approximately $84,000. Certuity LLC purchased a new position in Revance Therapeutics in the second quarter valued at $26,000. Victory Capital Management Inc. purchased a new position in Revance Therapeutics in the fourth quarter valued at $93,000. HighPoint Advisor Group LLC acquired a new position in Revance Therapeutics during the 4th quarter worth $98,000. Finally, Clarity Capital Partners LLC purchased a new stake in Revance Therapeutics during the 1st quarter worth about $59,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.